Latest research on TNF-R2

Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids

TNF-R2 dosage

To investigate the effects of TNF-α on acute liver injury, different doses of Enbrel were pretreated 15 min before CCl4 administered. [source, 2016]
However, as TNF-α was sequentially blocked at high dose of Enbrel (4 and 8 mg/kg), the ALT and AST levels were increased instead and reached the maximum at 8 mg/kg Enbrel when litter serum TNF-α was detected (Fig. 1c). [source, 2016]
We found there were almost no hepatocellular apoptosis during the process of increasing doses of Enbrel in the rats without administration of CCl4. [source, 2016]
However, in CCl4-induced rats, the expression of IL-6, IL-8, IL-β and IFN-γ were decreased as the concentration of TNF-α was blocked by increased dose of Enbrel, (Fig. 3a–d) while IL-4 had a completely opposite outcome (Fig. 3e). [source, 2016]
As TNF-α was blocked at high dose of Enbrel, pro-inflammatory factors were hardly detected. [source, 2016]
And their decreased extents were also dose-dependent on Enbrel. [source, 2016]
Enbrel at dose of 0, 0.25, 0.5, 1, 2, 4 or 8 mg/kg was intraperitoneally administered to the CCl4-injected rats 15 min before the CCl4 injection. [source, 2016]
After a stable baseline of blood pressure was obtained for 3 days, continuous renal interstitial infusion of TNFα inhibitor Etanercept (Enbrel, Amgen, Thousand Oaks, CA) at a dose of 0.25 mg/kg/day, or saline control, was initiated. [source, 2016]
Mice were treated with PBS, bortezomib (Millennium Pharmaceuticals, Cambridge, MA) at the doses of 0.75 or 0.15 mg/kg (Velcade (H) and (L) groups, resp.), or etanercept (Enbrel, Wyeth Pharmaceuticals, Hampshire, UK) at the dose of 5 mg/kg in 0.1 mL by i.p. injection twice a week starting on the day of EAU induction. [source, 2015]
Similarly, CL-NPs’ dose-dependent decreased proliferation (Figure 11B) and death receptors (Figure 11C) was observed by more significant reduction in Ki-67 and PCNA and TNF-R1, TNF-R2 and Fas protein expressions compared to CL alone. [source, 2015]